| Literature DB >> 17184879 |
Jacob A Sepmeyer1, John P Greer, Tatsuki Koyama, John A Zic.
Abstract
Four patients with stable or progressive cutaneous T-cell lymphoma treated with oral bexarotene received oral rosiglitazone. After 16 weeks of combination therapy, skin score decreased in two patients. Pruritus was alleviated in 3 of 4 patients, whereas quality of life was unchanged. Adverse events included hyperlipidemia, anemia, neutropenia, and lymphopenia.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17184879 DOI： 10.1016/j.jaad.2006.10.033
Source DB: PubMed Journal: J Am Acad Dermatol ISSN： 0190-9622 Impact factor: 11.527